Cabozantinib for progressive metastatic medullary thyroid cancer: a review
نویسندگان
چکیده
Medullary thyroid cancer is uncommon and patients typically present with advanced disease. Treatment options for patients with progressive, metastatic medullary thyroid cancer had been limited until recently. Tyrosine kinase inhibitors have garnered increasing interest in this subset of patients. The US Food and Drug Administration recently approved cabozantinib, a tyrosine kinase inhibitor, after promising results were shown in a large Phase III clinical trial. This review summarizes the clinical pharmacology, clinical trials, and safety data for cabozantinib and concludes with a discussion of possible future directions for the treatment of medullary thyroid cancer.
منابع مشابه
Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature
Cabozantinib, a tyrosine kinase inhibitor, was approved by the US Food and Drug Administration in November 2012, for the treatment of metastatic medullary thyroid carcinoma. Although side effects typically include stomatitis, palmar-plantar erythrodysesthesia syndrome, hypertension and diarrhea, most patients are able to tolerate the recommended dose of 140 mg daily. Surgical resection is the p...
متن کاملNEW DRUGS Cometriq for Thyroid Cancer
NEW DRUGS Cometriq for Thyroid Cancer Cabozantinib (Cometriq, Exelixis) has been approved with an orphan drug designation to treat metastatic medullary thyroid cancer (MTC). Cabozantinib blocks abnormal kinase proteins involved in the development and growth of medullary cancer cells. In a clinical study, treatment with cabozantinib increased progression-free survival and, in some patients, redu...
متن کاملNew drugs for medullary thyroid cancer: new promises?
Medullary thyroid cancer (MTC) is a rare tumor arising from the calcitonin-producing parafollicular C cells of the thyroid gland, occurring either sporadically or alternatively in a hereditary form based on germline RET mutations in approximately one-third of cases. Historically, patients with advanced, metastasized MTC have had a poor prognosis, partly due to limited response to conventional c...
متن کاملThyroid carcinoma, version 2.2014.
These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or ca...
متن کاملSafety and efficacy of vandetanib in the treatment of medullary thyroid cancer
Medullary thyroid cancer (MTC) is a rare malignancy affecting the calcitonin producing cells of the thyroid gland. Surgery is the mainstay of treatment in early stages. However in advanced or metastatic disease, there are few efficacious therapies. Recently emerging targeted treatments have shown promising results in this disease. Two such therapies, vandetanib and cabozantinib, have recently b...
متن کامل